Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Signature Cord Prime in Knee Osteoarthritis
NCT05234489Phase 1Unknown
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Biologic, TE (Tissue engineering), RM (Regenerative Medicine)
01
Overview
Phase 1, open-label trial of Signature Cord Prime in osteoarthritis (OA) (2 arms). Primary endpoint: Safety and Tolerability of Signature Cord Prime at 90 days. Status: unknown.
02
Drugs
Signature Cord Prime
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05234489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05234489.